Skip to main content
Journal cover image

Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.

Publication ,  Journal Article
Aggarwal, R; Oddis, CV; Goudeau, D; Koontz, D; Qi, Z; Reed, AM; Ascherman, DP; Levesque, MC
Published in: Rheumatology (Oxford)
June 2016

OBJECTIVES: To determine the longitudinal trends in serum levels of four myositis-associated autoantibodies: anti-Jo-1, -transcription intermediary factor 1 γ (TIF1-γ), -signal recognition particle (SRP) and -Mi-2, after B cell depletion with rituximab, and to determine the longitudinal association of these autoantibody levels with disease activity as measured by myositis core-set measures (CSMs). METHODS: Treatment-resistant adult and pediatric myositis subjects (n = 200) received rituximab in the 44-week Rituximab in Myositis Trial. CSMs [muscle enzymes, manual muscle testing (MMT), physician and patient global disease activity, HAQ, and extramuscular disease activity] were evaluated monthly and anti-Jo-1 (n = 28), -TIF1-γ (n = 23), -SRP (n = 25) and -Mi-2 (n = 26) serum levels were measured using validated quantitative ELISAs. Temporal trends and the longitudinal relationship between myositis-associated autoantibodies levels and CSM were estimated using linear mixed models. RESULTS: Following rituximab, anti-Jo-1 levels decreased over time (P < 0.001) and strongly correlated with all CSMs (P < 0.008). Anti-TIF1-γ levels also decreased over time (P < 0.001) and were only associated with HAQ, MMT and physician and patient global disease activity. Anti-SRP levels did not change significantly over time, but were significantly associated with serum muscle enzymes. Anti-Mi-2 levels significantly decreased over time and were associated with muscle enzymes, MMT and the physician global score. CONCLUSION: Anti-Jo-1, anti-TIF1-γ and anti-Mi-2 levels in myositis subjects decreased after B cell depletion and were correlated with changes in disease activity, whereas anti-SRP levels were only associated with longitudinal muscle enzyme levels. The strong association of anti-Jo-1 levels with clinical outcomes suggests that anti-Jo-1 autoantibodies may be a good biomarker for disease activity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

June 2016

Volume

55

Issue

6

Start / End Page

991 / 999

Location

England

Related Subject Headings

  • Treatment Outcome
  • Transcription Factors
  • Signal Recognition Particle
  • Severity of Illness Index
  • Rituximab
  • Myositis
  • Muscle, Skeletal
  • Middle Aged
  • Mi-2 Nucleosome Remodeling and Deacetylase Complex
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aggarwal, R., Oddis, C. V., Goudeau, D., Koontz, D., Qi, Z., Reed, A. M., … Levesque, M. C. (2016). Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford), 55(6), 991–999. https://doi.org/10.1093/rheumatology/kev444
Aggarwal, Rohit, Chester V. Oddis, Danielle Goudeau, Diane Koontz, Zengbiao Qi, Ann M. Reed, Dana P. Ascherman, and Marc C. Levesque. “Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.Rheumatology (Oxford) 55, no. 6 (June 2016): 991–99. https://doi.org/10.1093/rheumatology/kev444.
Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016 Jun;55(6):991–9.
Aggarwal, Rohit, et al. “Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.Rheumatology (Oxford), vol. 55, no. 6, June 2016, pp. 991–99. Pubmed, doi:10.1093/rheumatology/kev444.
Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, Ascherman DP, Levesque MC. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016 Jun;55(6):991–999.
Journal cover image

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

June 2016

Volume

55

Issue

6

Start / End Page

991 / 999

Location

England

Related Subject Headings

  • Treatment Outcome
  • Transcription Factors
  • Signal Recognition Particle
  • Severity of Illness Index
  • Rituximab
  • Myositis
  • Muscle, Skeletal
  • Middle Aged
  • Mi-2 Nucleosome Remodeling and Deacetylase Complex
  • Male